Literature DB >> 7870920

Differential effects of intra-accumbens and systemic amphetamine on latent inhibition using an on-baseline, within-subject conditioned suppression paradigm.

A S Killcross1, T W Robbins.   

Abstract

Latent inhibition (LI) is a phenomenon in which repeated, non-reinforced presentation of a stimulus retards subsequent conditioning to that stimulus. Several recent experiments have suggested that LI is abolished following acute, low doses of amphetamine given during pre-exposure and conditioning, and this effect has been attributed to amphetamine-induced changes in dopamine levels in the nucleus accumbens. Experiments 1 and 2 examined the effects of two doses of intra-accumbens d-amphetamine (10 micrograms/microliters and 3 micrograms/microliters) on LI in an on-baseline, within-subject conditioned suppression paradigm. There was no effect of either dose on LI, but a significant disinhibition of conditioned suppression resulted in a retardation of learning. In experiment 3 the effects of a low dose of systemic d-amphetamine (0.5 mg/kg) on latent inhibition were examined. The results replicated the abolition of LI found in previous studies, and demonstrated enhanced post-shock suppression in amphetamine-treated animals. These data provide no evidence for the involvement of the mesolimbic dopamine system in LI.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7870920     DOI: 10.1007/bf02244656

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  41 in total

1.  6-Hydroxydopamine lesions of the nucleus accumbens, but not of the caudate nucleus, attenuate enhanced responding with reward-related stimuli produced by intra-accumbens d-amphetamine.

Authors:  J R Taylor; T W Robbins
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

2.  The dose-response effect of amphetamine upon avoidance behaviour in the rat seen as a function of increasing stereotypy.

Authors:  M Lyon; A Randrup
Journal:  Psychopharmacologia       Date:  1972

3.  Differential performance of acute and chronic schizophrenics in a latent inhibition task.

Authors:  I Baruch; D R Hemsley; J A Gray
Journal:  J Nerv Ment Dis       Date:  1988-10       Impact factor: 2.254

4.  Response to stress of mesocortico-frontal dopaminergic neurones in rats after long-term isolation.

Authors:  G Blanc; D Hervé; H Simon; A Lisoprawski; J Glowinski; J P Tassin
Journal:  Nature       Date:  1980-03-20       Impact factor: 49.962

5.  The pharmacological and anatomical substrates of the amphetamine response in the rat.

Authors:  I Creese; S D Iversen
Journal:  Brain Res       Date:  1975-01-17       Impact factor: 3.252

6.  Dopaminergic mechanisms and cognitive deficit in schizophrenia. A neurobiological model.

Authors:  M H Joseph; C D Frith; J L Waddington
Journal:  Psychopharmacology (Berl)       Date:  1979-06-21       Impact factor: 4.530

7.  Localized intracaudate dopamine D2 receptor activation during the post-training period improves memory for visual or olfactory conditioned emotional responses in rats.

Authors:  N M White; M Viaud
Journal:  Behav Neural Biol       Date:  1991-05

8.  Latent inhibition is not affected by acute or chronic administration of 6 mg/kg dl-amphetamine.

Authors:  I Weiner; A Izraeli-Telerant; J Feldon
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

Review 9.  Neural substrates of latent inhibition: the switching model.

Authors:  I Weiner
Journal:  Psychol Bull       Date:  1990-11       Impact factor: 17.737

Review 10.  Limbic-striatal interactions in reward-related processes.

Authors:  T W Robbins; M Cador; J R Taylor; B J Everitt
Journal:  Neurosci Biobehav Rev       Date:  1989 Summer-Fall       Impact factor: 8.989

View more
  16 in total

1.  The on-baseline latent inhibition effect is not counterconditioning.

Authors:  A S Killcross; A Dickinson; T W Robbins
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

2.  Latent inhibition: interpretation of amphetamine effects in novel paradigms.

Authors:  M H Joseph
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

3.  Pre-exposure enhances recovery of conditioned responding after extinction.

Authors:  Hannah Rosenberg; Nathan M Holmes; Justin A Harris; R Frederick Westbrook
Journal:  Learn Behav       Date:  2011-09       Impact factor: 1.986

4.  Rethinking the emotional brain.

Authors:  Joseph LeDoux
Journal:  Neuron       Date:  2012-02-23       Impact factor: 17.173

5.  Effects of nicotine and amphetamine on latent inhibition in human subjects.

Authors:  J C Thornton; S Dawe; C Lee; C Capstick; P J Corr; P Cotter; S Frangou; N S Gray; M A Russell; J A Gray
Journal:  Psychopharmacology (Berl)       Date:  1996-09       Impact factor: 4.530

6.  A rat model of distractibility: effects of drugs modifying dopaminergic, noradrenergic and GABAergic neurotransmission.

Authors:  A Agmo; C Belzung; C Rodríguez
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

7.  Differences in serotonin and dopamine metabolism in the rat brain in latent inhibition.

Authors:  G F Molodtsova
Journal:  Neurosci Behav Physiol       Date:  2003-03

8.  Potentiation of amphetamine-induced locomotor activity following NMDA-induced retrohippocampal neuronal loss in the rat.

Authors:  B K Yee; J Feldon; J N Rawlins
Journal:  Exp Brain Res       Date:  1995       Impact factor: 1.972

9.  Latent inhibition in 35-day-old rats is not an "adult" latent inhibition: implications for neurodevelopmental models of schizophrenia.

Authors:  L Zuckerman; N Rimmerman; I Weiner
Journal:  Psychopharmacology (Berl)       Date:  2003-06-24       Impact factor: 4.530

10.  Disruption of latent inhibition induced by ovariectomy can be reversed by estradiol and clozapine as well as by co-administration of haloperidol with estradiol but not by haloperidol alone.

Authors:  Michal Arad; Ina Weiner
Journal:  Psychopharmacology (Berl)       Date:  2009-01-25       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.